Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.
Review published in Heart disease (Hagerstown, Md.) (2001)
Abstract
Argatroban, a direct thrombin inhibitor derived from arginine, is an effective anticoagulant indicated for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Argatroban has been used as an alternative anticoagulant in patients with HIT in various clinical conditions including interventional cardiovascular procedures that require anticoagulation. Satisfactory clinical outcomes with acceptable complications have been reported in these patients. Whether argatroban offers additional clinical advantage over conventional heparin therapy in patients without HIT remains unclear. Argatroban has been evaluated as an alternative anticoagulant to replace heparin in various clinical studies, especially in patients with coronary artery disease or cerebral vascular disease. To date, it remains unclear if argatroban is more effective than heparin, although the agent seems to cause less bleeding complications. This article reviews the pharmacology of argatroban and its clinical application beyond the management of HIT, with particular emphasis on interventional cardiology procedure, acute myocardial infarction, unstable angina pectoris, cerebral thrombosis or ischemic stroke, peripheral obstructive arterial disease, and extracorporeal circulation.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Argatroban, a direct thrombin inhibitor derived from arginine, is an effective anticoagulant indicated for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).
Why This Matters for Hirudotherapy
This narrative review surveys argatroban, a synthetic arginine-derived direct thrombin inhibitor, as an alternative anticoagulant in heparin-induced thrombocytopenia (HIT) and in cardiovascular indications such as coronary intervention, acute myocardial infarction, ischemic stroke and extracorporeal circulation; the author notes acceptable outcomes in HIT but states it remains unclear whether argatroban outperforms heparin in non-HIT patients, though it appears to cause fewer bleeding complications. For ASH, it is useful background on direct thrombin inhibition as a therapeutic principle: the medicinal-leech secretome's signature molecule, hirudin, is itself a natural direct thrombin inhibitor, so this article helps frame where leech-derived antithrombins sit conceptually alongside an established small-molecule drug. The caveat is that this is a review of argatroban only, makes no claim about leech therapy, and the question of superiority over heparin is left explicitly unresolved by the author.
Citation
Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.
Chen JL · Heart disease (Hagerstown, Md.), 2001
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026